What is the success rate of Cabometyx (cabozantinib)?
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor used to treat certain patients with advanced renal cell carcinoma, hepatocellular (liver) cancer, differentiated thyroid cancer, or pancreatic and extra-pancreatic neuroendocrine tumors.
It is a targeted chemotherapy drug that you take until your cancer starts to get worse - disease progression - or you can no longer tolerate the drug because of side effects or adverse reactions.
How successful Cabometyx is can be measured by how long patients take the treatment for, how long they survive for without their cancer getting worse (progression-free survival), how many months they remain alive for while taking the treatment and how many patients respond to the drug.
How effective is Cabometyx?
| Trial | Duration of treatment | Median progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) |
| METEOR - advanced renal cell carcinoma |
Cabometyx: 7.6 months (range 0.3 - 20.5) vs Everolimus (Afinitor): 4.4 months (range 0.21 - 18.9) |
PFS Cabometyx: 7.4 months (95% CI 5.6, 9.1) vs Everolimus: 3.8 months (95% CI 3.7, 5.4) OS Partial responses only Cabometyx: 17% (95% CI 13%, 22%) vs Everolimus: 3% (95% CI 2%, 6%) |
| CABOSUN - advance renal cell carcinoma |
Cabometyx: 6.5 months (range 0.2 - 28.7) vs Sunitinib (Sutent): 3.1 months (range 0.2 - 25.5) |
PFS Cabometyx: 8.6 months (95% CI 6.8, 14.0) vs Everolimus: 5.3 months (95% CI 3.0, 8.2) ORR |
| CHECKMATE-9ER - advanced renal cell carcinoma, first-line treatment | Cabometyx plus nivolumab (Opdivo): 14 months (range 0.2 - 27) |
PFS Cabometyx: 16.6 months (95% CI 12.5, 24.9) vs Sunitinib: 8.3 months (95% CI 7.0, 9.7) OS Complete and partial responses Cabometyx: 55.7% (95% CI 50.1, 61.2) vs Sunitinib: 27.1% (95% CI 22.4, 32.3) |
| CELESTIAL - advanced hepatocellular carcinoma |
Cabometyx: 3.8 months (range 0.1 - 37.3) vs Placeo: 2.0 months (range 0.0 - 27.2) |
PFS Cabometyx: 5.2 months (95% CI 4.0, 5.5) vs Placebo: 1.9 months (95% CI 1.9, 1.9) OS Partial responses only Cabometyx: 4% (95% CI2.3, 6.0) vs Placebo: 0.4% (95% CI 0.0, 2.3) |
| COSMIC-311 - radioiodine-refractory differentiated thyroid cancer previously treated with VEGFR-targeted therapy |
PFS (updated analysis) Cabometyx: 11 months (95% CI 7.4, 13.8) vs Placebo: 1.9 months (95% CI 1.9, 3.7) ORR (updated analysis) |
|
| CABINET - pancreatic and extrapancreatic neuroendocrine tumors (pNET and epNET) |
PFS (pNET)
|
Related questions
References
- Cabometyx Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208692s017lbl.pdf
- Chan, J. A., Geyer, S., Zemla, T., Knopp, M. V., Behr, S., Pulsipher, S., ... Meyerhardt, J. A. (2024). Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. New England Journal of Medicine, 392(7), 653-665. https://doi.org/10.1056/NEJMoa2403991
Read next
How does Cabometyx work?
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor, which works by helping to stop the out-of-control growth that cancer cells display.
Carbometyx works by blocking the signals between cells that promote the growth of new blood vessels and encourage cells to divide and grow. In doing so, it decreases the ability of tumors to spread (metastasize) to other parts of the body and invade surrounding areas. Continue reading
What is the difference between Cabometyx and Cometriq?
Cabometyx and Cometriq are two brand name drugs that both contain the same active ingredient cabozantinib, but they are not interchangeable.
Cabometyx comes in the form of a tablet (20, 40 and 60 mg) and is used to treat advanced renal cell carcinoma (RCC), advanced RCC as a first-line treatment in combination with nivolumab, hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib, certain types of differentiated thyroid cancer, and pancreatic or extra-pancreatic neuroendocrine tumors (pNET and epNET).
Cometriq comes in the form of a capsule (20 and 80 mg) and is used to treat progressive metastatic medullary thyroid cancer. Continue reading
What is the success rate of Keytruda?
In general, PD-1 immune checkpoint inhibitors like Keytruda have been shown to significantly prolong overall survival (OS) in some patients with various cancer types, but Keytruda does not always work for everyone. Continue reading
Related medical questions
- How long does it take for Keytruda to work?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: How do they compare?
- How long does it take for Lenvima to work?
- How long do you take Lenvima?
- How does Nexavar work? Is it a chemo drug?
- How much does Afinitor cost per month?
- How are Inlyta and Keytruda used in kidney cancer?
- What is the difference between Mvasi and Avastin?
- How effective is Nexavar? Does it shrink tumors?
- How long can you take Afinitor for?
- Does Votrient cure cancer or shrink tumors?
- What type of drug is Lenvima? Is it a chemo drug?
- How effective are Opdivo and Yervoy when taken together?
- How long do you take Sutent before it starts to work?
- Opdivo vs Opdivo Qvantig: What is the Difference?
- Does Sutent shrink tumors?
- How effective is Lenvima?
- Is Nexavar cost covered by Medicare?
- Is Sutent considered a chemotherapy drug?
- How long does Votrient stay in your system?
- Is Votrient a chemotherapy treatment?
- Is Votrient immunotherapy?
- Who makes Bavencio and where is it made?
- What type of drug is Bavencio?
Drug information
Related support groups
- Cabometyx (7 questions, 10 members)
- Cabozantinib (5 questions, 6 members)
- Renal Cell Carcinoma (32 questions, 103 members)
- Hepatocellular Carcinoma (22 questions, 23 members)
- Thyroid Cancer (13 questions, 44 members)